514 related articles for article (PubMed ID: 34514439)
1. Acute exercise increases immune responses to SARS CoV-2 in a previously infected man.
Baker FL; Smith KA; Zúñiga TM; Batatinha H; Niemiro GM; Pedlar CR; Burgess SC; Katsanis E; Simpson RJ
Brain Behav Immun Health; 2021 Dec; 18():100343. PubMed ID: 34514439
[TBL] [Abstract][Full Text] [Related]
2. Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2.
Baker FL; Zúñiga TM; Smith KA; Batatinha H; Kulangara TS; Seckeler MD; Burgess SC; Katsanis E; Simpson RJ
Brain Behav Immun Health; 2023 Mar; 28():100600. PubMed ID: 36743994
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccination produces exercise-responsive SARS-CoV-2 specific T-cells regardless of infection history.
Smith KA; Zúñiga TM; Baker FL; Batatinha H; Pedlar CR; Burgess SC; Gustafson MP; Katsanis E; Simpson RJ
J Sport Health Sci; 2024 Jan; 13(1):99-107. PubMed ID: 37399887
[TBL] [Abstract][Full Text] [Related]
4. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
5. Dominant CD8
Taus E; Hofmann C; Ibarrondo FJ; Hausner MA; Fulcher JA; Krogstad P; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
Front Immunol; 2022; 13():835830. PubMed ID: 35273611
[TBL] [Abstract][Full Text] [Related]
6. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
7. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
9. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B
Front Immunol; 2022; 13():942192. PubMed ID: 36275696
[TBL] [Abstract][Full Text] [Related]
10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
11. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
12. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
13. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
Groß-Albenhausen E; Weier A; Velten M; Heider T; Chunder R; Kuerten S
Front Immunol; 2023; 14():1254128. PubMed ID: 37841269
[TBL] [Abstract][Full Text] [Related]
14. CD8
Ford ES; Mayer-Blackwell K; Jing L; Sholukh AM; St Germain R; Bossard EL; Xie H; Pulliam TH; Jani S; Selke S; Burrow CJ; McClurkan CL; Wald A; Holbrook MR; Eaton B; Eudy E; Murphy M; Postnikova E; Robins HS; Elyanow R; Gittelman RM; Ecsedi M; Wilcox E; Chapuis AG; Fiore-Gartland A; Koelle DM
Res Sq; 2022 Oct; ():. PubMed ID: 36263073
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity.
Lin J; Law R; Korosec CS; Zhou C; Koh WH; Ghaemi MS; Samaan P; Ooi HK; Matveev V; Yue F; Gingras AC; Estacio A; Buchholz M; Cheatley PL; Mohammadi A; Kaul R; Pavinski K; Mubareka S; McGeer AJ; Leis JA; Heffernan JM; Ostrowski M
J Virol; 2022 Jul; 96(13):e0050922. PubMed ID: 35699447
[TBL] [Abstract][Full Text] [Related]
16. T cell responses to whole SARS coronavirus in humans.
Li CK; Wu H; Yan H; Ma S; Wang L; Zhang M; Tang X; Temperton NJ; Weiss RA; Brenchley JM; Douek DC; Mongkolsapaya J; Tran BH; Lin CL; Screaton GR; Hou JL; McMichael AJ; Xu XN
J Immunol; 2008 Oct; 181(8):5490-500. PubMed ID: 18832706
[TBL] [Abstract][Full Text] [Related]
17. Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens.
Mysore V; Cullere X; Settles ML; Ji X; Kattan MW; Desjardins M; Durbin-Johnson B; Gilboa T; Baden LR; Walt DR; Lichtman AH; Jehi L; Mayadas TN
Med; 2021 Sep; 2(9):1050-1071.e7. PubMed ID: 34414383
[TBL] [Abstract][Full Text] [Related]
18. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
19. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
Front Immunol; 2022; 13():907125. PubMed ID: 35784359
[TBL] [Abstract][Full Text] [Related]
20. Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders.
Algu P; Hameed N; DeAngelis T; Stern J; Harel A
Mult Scler Relat Disord; 2023 Nov; 79():104965. PubMed ID: 37657307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
